H
Hung-Jui Tan
Researcher at University of North Carolina at Chapel Hill
Publications - 87
Citations - 2982
Hung-Jui Tan is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 21, co-authored 73 publications receiving 2117 citations. Previous affiliations of Hung-Jui Tan include University of California, Los Angeles & University of Michigan.
Papers
More filters
Journal ArticleDOI
The Diagnosis and Treatment of Prostate Cancer: A Review.
Mark S. Litwin,Hung-Jui Tan +1 more
TL;DR: Advances in the diagnosis and treatment of prostate cancer have improved the ability to stratify patients by risk and allowed clinicians to recommend therapy based on cancer prognosis and patient preference.
Journal ArticleDOI
Long-term Survival Following Partial vs Radical Nephrectomy Among Older Patients With Early-Stage Kidney Cancer
TL;DR: Among Medicare beneficiaries with early-stage kidney cancer who were candidates for either surgery, treatment with partial rather than radical nephrectomy was associated with improved survival, and no difference was noted in kidney cancer-specific survival.
Journal ArticleDOI
Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.
Nicholas M. Donin,Christopher P. Filson,Christopher P. Filson,Alexandra Drakaki,Hung-Jui Tan,Alex Castillo,Lorna Kwan,Mark S. Litwin,Karim Chamie +8 more
TL;DR: In the current study, the authors attempted to describe the incidence, most common sites, and mortality of second primary malignancies among survivors of common cancers.
Journal ArticleDOI
Preoperatively Misclassified, Surgically Removed Benign Renal Masses: A Systematic Review of Surgical Series and United States Population Level Burden Estimate
David C. Johnson,Josip Vukina,Angela M Smith,Anne Marie Meyer,Stephanie B. Wheeler,Tzy Mey Kuo,Hung-Jui Tan,Michael Woods,Mathew C. Raynor,Eric Wallen,Raj S. Pruthi,Matthew E. Nielsen +11 more
TL;DR: The population level burden of preoperatively misclassified benign renal masses is substantial and increasing rapidly, paralleling increases in surgically resected small renal cell carcinoma.
Journal ArticleDOI
Utilizing time‐driven activity‐based costing to understand the short‐ and long‐term costs of treating localized, low‐risk prostate cancer
Aaron A. Laviana,Annette M. Ilg,Darlene Veruttipong,Hung-Jui Tan,Michael A. Burke,Douglas Niedzwiecki,Patrick A. Kupelian,Christopher R. King,Michael L. Steinberg,Chandan R. Kundavaram,Mitchell Kamrava,Alan L. Kaplan,Andrew K. Moriarity,William Hsu,Daniel Margolis,Jim C. Hu,Christopher S. Saigal +16 more
TL;DR: The results of time‐driven activity‐based costing (TDABC) for competing treatments of low‐risk prostate cancer for men with prostate cancer are reported.